Summit Therapeutics Inc. (SMMT)
NASDAQ: SMMT · Real-Time Price · USD
14.48
-0.92 (-5.97%)
At close: Jan 30, 2026, 4:00 PM EST
14.30
-0.18 (-1.24%)
After-hours: Jan 30, 2026, 7:58 PM EST
Summit Therapeutics Employees
Summit Therapeutics had 159 employees as of December 31, 2024. The number of employees increased by 54 or 51.43% compared to the previous year.
Employees
159
Change (1Y)
54
Growth (1Y)
51.43%
Revenue / Employee
n/a
Profits / Employee
-$5,796,333
Market Cap
11.17B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2024 | 159 | 54 | 51.43% |
| Dec 31, 2023 | 105 | 28 | 36.36% |
| Dec 31, 2022 | 77 | -33 | -30.00% |
| Dec 31, 2021 | 110 | 29 | 35.80% |
| Dec 31, 2020 | 81 | 11 | 15.71% |
| Dec 31, 2019 | 70 | 9 | 14.75% |
| Dec 31, 2018 | 61 | -15 | -19.74% |
| Dec 31, 2017 | 76 | 36 | 90.00% |
| Dec 31, 2016 | 40 | 3 | 8.11% |
| Dec 31, 2015 | 37 | 14 | 60.87% |
| Dec 31, 2014 | 23 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
| Company Name | Employees |
|---|---|
| Bio-Techne | 3,100 |
| BioMarin Pharmaceutical | 3,040 |
| Jazz Pharmaceuticals | 2,800 |
| Exelixis | 1,147 |
| Ionis Pharmaceuticals | 1,069 |
| Ascendis Pharma | 1,017 |
| Axsome Therapeutics | 816 |
| Roivant Sciences | 750 |
SMMT News
- 11 hours ago - Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 1 day ago - Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy - Business Wire
- 18 days ago - Summit Therapeutics Inc. (SMMT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript - Seeking Alpha
- 18 days ago - Summit Therapeutics Announces Clinical Trial Collaboration with GSK to Evaluate Ivonescimab in Combination with GSK's B7-H3 Antibody Drug Conjugate (ADC) - Business Wire
- 18 days ago - Summit Therapeutics Announces Submission of Biologics License Application (BLA) to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC - Business Wire
- 21 days ago - Summit Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
- 24 days ago - Summit Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference - Business Wire
- 2 months ago - Summit Therapeutics Inc. (SMMT) Presents at Evercore 8th Annual Healthcare Conference Transcript - Seeking Alpha